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Abstract
Background: We compared the prevalence, awareness, treatment, and control of hypertension in Iran based on two
hypertension guidelines; the 2017 ACC/AHA –with an aggressive blood pressure target of 130/80mmHg- and the
commonly used JNC8 guideline cut-off of 140/90mmHg. We shed light on the implications of the 2017 ACC/AHA for
population subgroups and high-risk individuals who were eligible for non-pharmacologic and pharmacologic therapies.
Methods: Data was obtained from the Iran national STEPS 2016 study. Participants included 27,738 adults aged ≥25 years
as a representative sample of Iranians. Regression models of survey design were used to examine the determinants of
prevalence, awareness, treatment, and control of hypertension.
Results: The prevalence of hypertension based on JNC8 was 29.9% (95% CI: 29.2–30.6), which soared to 53.7% (52.9–54.4)
based on the 2017 ACC/AHA. The percentage of awareness, treatment, and control were 59.2% (58.0–60.3), 80.2% (78.9–
81.4), and 39.1% (37.4–40.7) based on JNC8, which dropped to 37.1% (36.2–38.0), 71.3% (69.9–72.7), and 19.6% (18.3–21.0),
respectively, by applying the 2017 ACC/AHA. Based on the new guideline, adults aged 25–34 years had the largest
increase in prevalence (from 7.3 to 30.7%). They also had the lowest awareness and treatment rate, contrary to the
highest control rate (36.5%) between age groups. Compared with JNC8, based on the 2017 ACC/AHA, 24, 15, 17, and
11% more individuals with dyslipidaemia, high triglycerides, diabetes, and cardiovascular disease events, respectively, fell
into the hypertensive category. Yet, based on the 2017 ACC/AHA, 68.2% of individuals falling into the hypertensive
category were eligible for receiving pharmacologic therapy (versus 95.7% in JNC8). LDL cholesterol< 130mg/dL, sufficient
physical activity (Metabolic Equivalents≥600/week), and Body Mass Index were found to change blood pressure by
− 3.56(− 4.38, − 2.74), − 2.04(− 2.58, − 1.50), and 0.48(0.42, 0.53) mmHg, respectively.
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Conclusions: Switching from JNC8 to 2017 ACC/AHA sharply increased the prevalence and drastically decreased the
awareness, treatment, and control in Iran. Based on the 2017 ACC/AHA, more young adults and those with chronic
comorbidities fell into the hypertensive category; these individuals might benefit from earlier interventions such as
lifestyle modifications. The low control rate among individuals receiving treatment warrants a critical review of
hypertension services.
Keywords: Hypertension, JNC8 hypertension guideline, 2017 ACC/AHA hypertension guideline, Effective coverage,
Prevalence, Awareness, Treatment, Control, Iran
Background
Hypertension (HTN) is the leading modifiable risk factor
for premature morbidity and mortality in the world and
Iran. The prevalence of HTN is rising globally [1]. In
2000, 26.4% of the world’s adults had HTN, which is ex-
pected to reach 29.2% by 2025 [2]. Among Iranians aged
25–70 years, 24.1% were living with HTN in 2011 [3].
The fact that a large proportion of the population is liv-
ing with HTN and its costly comorbidities make it a
health priority and a tracer for measuring progress to-
wards Universal Health Coverage (UHC).
The definition of hypertension, which determines a cut-
off for hypertension diagnosis, directly affects the esti-
mates made for the UHC of hypertension i.e. prevalence,
awareness, treatment and control, and subsequently, the
treatment costs incurred by health systems for hyperten-
sion control. Following the release of the 2017 ACC/AHA
Guideline for the Prevention, Detection, Evaluation, and
Management of High Blood Pressure in Adults with the
cut-off of 130/80mmHg [4], a reasonable blood pressure
(BP) target for the effective coverage of hypertension has
become a heated debate [5]. For several years, guidelines
such as the JNC8 (with 140/90mmHg as its cut-off for
hypertension) were used to determine the prevalence,
awareness, treatment, and control of hypertension [6].
Studies have shown that switching from JNC8 to the
2017 ACC/AHA increases the prevalence of hypertension
[7, 8]. However, evidence on the implications of the 2017
ACC/AHA guideline on the awareness, treatment, and
control of hypertension is under-developed [9]. Despite
the potential health benefits of the 2017 ACC/AHA guide-
line [7, 8], adopting this guideline to enhance hypertension
control in low- and middle- income countries (LMICs) is
under question – given its economic impacts [10]. Ac-
cording to Watkins, the burden of the possibly higher
numbers of individuals that shift from the ‘elevated’ and
‘prehypertensive’ into the ‘hypertensive’ categories (based
on the 2017 ACC/AHA guideline) is hardly bearable by
the already-overburdened health systems of LMICs [11].
This counterargument warrants more empirical findings
per country in order to estimate the burden of embarking
on the 2017 ACC/AHA hypertension guideline.
In this study, we estimated the prevalence, awareness,
treatment, and control of HTN, based on the two ‘JNC8’
and ‘2017 ACC/AHA’ guidelines. We shed light on the
implications (and benefits) of adopting an intensified
blood pressure control recommended by the 2017 ACC/
AHA, for different subgroups of Iranian populations and
high-risk hypertensive adults using the 10-year athero-
sclerotic cardiovascular disease (ASCVD) risk score. We
compared the proportion of hypertensive individuals eli-
gible for pharmacologic therapy based on both guide-
lines and discussed the implications in terms of the
potential costs imposed on the Iranian health system to
provide treatment to adults eligible for pharmacologic
therapy.
Methods
Research design
We used the data collected in the ‘Iran STEPS 2016’
study. The WHO STEPwise approach to Surveillance
(STEPS) provided the grounds for conducting the Iran
STEPS 2016 study [12]. The Iran STEPS 2016 study in-
cluded a representative sample of the Iranian popula-
tion from urban and rural areas of 30 provinces, which
were selected based on a multistage random sampling
method. All Iranians aged > 18 years who were living in
Iran at the time of data collection were eligible for in-
clusion in the study. The original study questionnaire
was constructed by the WHO STEPS. It was translated
into Persian and was culturally adapted through learn-
ing from the application of the questionnaire in the
earlier STEPS studies conducted in 2005, 2006, 2007,
2008, 2009, and 2011. During this development process,
the consistency, validity, and reliability of the question-
naire were assessed. Data was collected by trained in-
terviewers through in-person interviews. The methods
employed in the Iran STEPS 2016 study which include
details on the sampling design, the validity and reliabil-
ity of the study questionnaire, the interview guide, and
data collection methods are presented elsewhere [13].
The interview guide was not developed for the present
study, but for the Iran STEPS 2016 study.
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Measures
Outcome definitions
The main outcomes consisted of prevalence, awareness,
treatment, and control of HTN. We distinguished hyperten-
sion based on the JNC8 and the 2017 ACC/AHA guidelines.
Based on JNC8, we considered individuals with systolic
blood pressure (SBP) ≥140mmHg or diastolic blood pres-
sure (DBP) ≥90mmHg as hypertensive; whereas, based on
2017 ACC/AHA, those with SBP ≥ 130mmHg or DBP ≥ 80
mmHg [4] were considered hypertensive. Furthermore, the
self-reported use of antihypertensive drugs in the last 2
weeks was considered as the presence of HTN for both defi-
nitions [14]. According to the WHO STEPS manual, trained
personnel measured blood pressure on the right upper-arm
three times, having had the participant rest for 5min in a
seated position [12]. An average of the last two measure-
ments was considered as the blood pressure measure.
Awareness was deemed to be present if an individual an-
swered ‘Yes’ to the question ‘Have you ever been diagnosed
with hypertension by a physician or a health professional?’
Treatment was defined as the self-reported use of antihyper-
tensive drugs among aware individuals. Hypertension con-
trol referred to an average SBP < 130 & DBP < 80mmHg
based on the 2017 ACC/AHA and an average SBP < 140 &
DBP < 90mmHg based on the JNC8.
Covariates
Covariates included demographic, socio-economic status
(SES), lifestyle, health insurance coverage, and cardiovas-
cular disease (CVD) risk factors. Demographic factors
included age, gender, marital status, and place of resi-
dence. Age groups consisted of 25–34, 35–44, 45–54,
55–64, 65–74, and 75+ years. Marital status included
two groups; single/divorced/widow and married. SES
comprised of wealth status and the years of schooling.
Wealth status was measured by the wealth index [15]
and was grouped into the poorest, poor, average, rich,
and richest. Based on the years of schooling, participants
were categorized into four groups; participants with no
schooling, 1–6 years, 7–12 years, and higher than 12
years of schooling. Insurance coverage referred to basic
and complementary health insurance. Basic health insur-
ance refers to a minimum coverage of essential health
services by public health insurance organizations. Com-
plementary health insurance is a coverage policy pro-
vided by private insurers that pays for surcharges of
medical services not covered by basic health insurance
or services delivered by private providers [16].
Lifestyle factors consisted of smoking, alcohol consump-
tion, intake of fruits and vegetables, salt intake, and physical
activity. Smoking has a dichotomy of statuses: never-
smoker/non-smoker and current daily cigarette smoker.
Smoker referred to a person who smoked cigarettes on a
daily basis at the time of the survey. Never-smoker/non-
smoker referred to a person who had never smoked or had
quitted smoking. Since evidence on the relationships be-
tween smoking and hypertension is controversial, we relied
on [17] comparing the outcomes between former-smokers
and never-smokers versus current-smokers. Furthermore,
only 70 (0.26%) study participants reported using tobacco
products other than cigarettes; whereas, 2911 (10.72%)
study participants reported that they were current cigarette
smokers. Consequently, smoking other tobacco products
was not included in the analysis and our analysis focused
on cigarette smoking. In terms of alcohol intake, we classi-
fied the participants into alcohol drinkers and non-
drinkers. An alcohol drinker referred to a person who had
consumed any type of alcohol product during the last 12
months before the time of the survey, regardless of the dur-
ation or frequency of consumption. Non-drinker referred
to a participant who had consumed no alcohol during the
same period of time. The intake of fruits and vegetables
was estimated for 24 h (24-h). We considered five portions
of fruits and vegetables, consisting of two portions of fruits
and three portions of vegetables, as a sufficient daily intake
based on the dietary guidelines [18]. One portion of fruits
referred to 80 g of fruits. In order to make the portion size
comprehensible to the study participants, ‘one medium-
sized fruit, like a medium-sized apple, or ¼th of a cup of
dried fruits’ was considered one portion of fruits. One por-
tion of vegetables equalled ‘one cup of raw leafy vegetables,
like spinach, or half a cup of cooked vegetables’.
The 24-h salt intake was estimated from spot-urine
samples using the Tanaka equation [19]:
2:54 1000 23 21:98
fspot sodium mmol=lð Þ= spot creatinine mg=dLð Þ  10½ 
½−2:04 age yearsð Þ þ 14:89 weight kgð Þ þ 16:14
height cmð Þ−2244:45g0:392
All spot urine samples were collected in the morning
between 8.00–10.00 a.m., and transferred to a central la-
boratory unit according to the 2016 STEPS study protocol
[13]. The detailed methods and results of applying the Ta-
naka equation to the Iran STEPS 2016 data have been
published elsewhere [20]. We analysed the relationships
between salt intake and outcomes using salt intake as a
continuous and dichotomized variable. Since only 2% of
the study sample had a salt intake of < 5 g/day, we consid-
ered 10 g/day as the cut-off. The complementary analysis
of relationships between daily salt intake and blood pres-
sure among hypertensive, aware, treatment-receiving, and
under-control individuals is presented in Additional File 1.
Physical activity was measured using the WHO Global
Physical Activity Questionnaire (GPAQ) version 2 with a
cut-off of metabolic equivalents (METs) ≥ 600/week as
sufficient [21]. Body Mass Index (BMI) had four levels;
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underweight (< 18.5 kg/m2), normal (18.5–24.9 km/m2),
overweight (25.0–29.9 kg/m2), and obesity (≥30 kg/m2).
CVD risk factors consisted of dyslipidaemia, high triglyc-
erides, diabetes mellitus (DM), and self-reported history of
CVDs, i.e. myocardial infarction and/or stroke [4]. Dyslipi-
daemia referred to either total cholesterol ≥200mg/dL,
high-density lipoprotein (HDL) cholesterol < 35mg/dL, or
low-density lipoprotein (LDL) cholesterol ≥130mg/dL.
High triglycerides referred to fasting triglycerides ≥200
mg/dL [22]. DM referred to HbA1c > 48mmol/mol or
fasting blood sugar (FBS) > 126mg/dL or self-reported
DM [23].
Statistical analysis
We calculated the ratio and 95% confidence interval (95%
CI) of prevalence, awareness, treatment, and control based
on cut-offs recommended by the JNC8 and 2017 ACC/
AHA. We constructed univariate and multiple logistic re-
gression models to account for the effects of covariates on
prevalence, awareness, treatment, and control based on
the 2017 ACC/AHA only. We calculated the number and
percentage of individuals eligible for pharmacologic ther-
apy based on both JNC8 [6] and the 2017 ACC/AHA. The
number of individuals eligible for nonpharmacologic ther-
apy was only determined based on the 2017 ACC/AHA,
which comprised elevated, HTN stage 1, and HTN stage 2
adults. Based on 2017 ACC/AHA, two groups were eli-
gible for pharmacologic therapy: a) individuals with BP
≥140/90, and b) those with BP ≥130/80 who had 10-year
atherosclerotic CVD (ASCVD) risk≥10%. The number of
adults eligible for pharmacologic therapy was also deter-
mined based on JNC8 [6]. Among individuals with BP
≥ 120/80mmHg, associations between blood pressure and
lifestyle factors, weight, BMI, physical activity, intake of
fruits and vegetables, 24-h intake of salt, LDL cholesterol,
and alcohol consumption were tested.
Given the multistage clustering structure, a complex
survey analysis was used to obtain summary measures
and statistical models. We weighted samples according
to the 2015 Iranian National Population Census. Logistic
regression models with a survey design was used to ana-
lyse associations between the outcomes and covariates.
We analysed the data using Stata 13 and R 3.4.1 statis-
tical software programs.
Results
The study sample included 27,738 participants who were
aged ≥25 years. Of these, 573 (2%) were excluded from
the analyses due to missing values of SBP or DBP mea-
surements. In the end, 27,165 participants were consid-
ered for analysis, of whom about 70% were between 25
and 54 years old.
We found that adopting 2017 ACC/AHA markedly in-
creased the prevalence. Based on JNC8, the prevalence was
29.9% (95% CI: 29.2–30.6), which soared to 53.7% (52.9–
54.4), based on the 2017 ACC/AHA (Table S1). Likewise,
the prevalence rate sharply increased by age from younger
to older groups, reaching its peak at 82.4% among those
≥75 years old (Odds Ratio (OR): 7.97 [6.29–10.10]) (Table
S1). Based on the 2017 ACC/AHA, the largest increase in
prevalence was observed in the 25–34-year-old age group;
the prevalence increased from 7.3% based on JNC8 to
30.7% based on the 2017 ACC/AHA.
The prevalence percentage was lower among females
(OR: 0.74 [0.67–0.82]) and rural dwellers (OR: 0.90 [0.80–
1.00]). Among the wealth groups, the richest group had
the lowest prevalence (OR: 0.69 [0.58–0.82]). The preva-
lence also significantly decreased from 73.7% among illit-
erates to 44.2% among those with > 12 years of schooling
(OR: 0.66 [0.55–0.79]). Prevalence significantly increased
from normal BMI to overweight (OR: 1.60 [1.44–1.78])
and obese (OR: 2.22 [1.97–2.51]). It was significantly
higher among those with dyslipidaemia (OR: 1.15 [1.05–
1.26]), high triglycerides (OR: 1.31 [1.15–1.49]), DM (OR:
1.58 [1.37–1.82]), and CVD history (OR: 1.77 [1.28–2.45]).
By lowering the blood pressure cut-off point by 10mmHg
to 130/80mmHg, 24, 15, 17, and 11% more individuals
with dyslipidaemia, high triglycerides, diabetes, and CVD
events, respectively, fell into the hypertensive category.
For instance, based on the JNC 8, 71.5% of individuals
with previous CVD events were considered hypertensive,
which increased to 82.5% based on the 2017 ACC/AHA
(Table S1).
Based on the JNC8, 59.2% (58.0–60.3) of hypertensive
individuals were aware; whereas, according to the 2017
ACC/AHA, 37.1% (36.2–38.0) were aware (Table S2).
Based on the 2017 ACC/AHA guideline, awareness sig-
nificantly increased by age, from 9.7% in the youngest to
67.9% in the oldest group (OR: 13.23 [9.54–18.37]). A
larger proportion of females (45.1%) were aware (OR:
1.59 [1.39–1.81]) compared to males (28.9%). Awareness
declined with increases in years of schooling, reaching
its lowest among the well-educated group (OR: 0.58
[0.46–0.73]). Patients with a higher awareness were more
likely to have complementary insurance coverage.
Awareness was significantly higher among the over-
weight (OR: 1.39 [1.19–1.62]) and obese (OR: 1.71 [1.44–
2.03]) groups. Individuals with salt ≥10 g/day were less
likely to be aware (OR: 0.87 [0.77–0.98]) and one gram/day
salt decreased the odds of awareness (OR: 0.96 [0.94–0.99])
(see also Additional File 1). Awareness was significantly
higher among individuals with DM (OR: 1.76 [1.52–2.05])
and a history of CVD (OR: 2.51 [1.79–3.52]).
Based on the JNC8, 80.2% (78.9–81.4) of hypertensive
individuals were receiving treatment, which decreased to
71.3% (69.9–72.7) when the 2017 ACC/AHA guideline
was considered (Table S3). Based on the 2017 ACC/AHA,
the ratio of treatment–receiving individuals increased by
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age (Table S3). The ORs of treatment increased from 2.83
(1.56–5.17) among the 35–44-year-old age group to 13.38
(6.83–26.24) among those ≥75 years old. Treatment per-
centage increased with insufficient physical activity (OR:
1.21 [1.00–1.47]). Diabetics were more likely than non-
diabetics to have received more treatment (OR: 1.79
[1.43–2.24]). Naturally, 92.2% of patients with CVD his-
tory were receiving treatment (OR: 3.02 [1.79–5.11]).
The control rate of HTN was 39.1% (37.4–40.7) based
on the JNC8. It dropped to 19.6% (18.3–21.0) based on
the 2017 ACC/AHA (Table S4). Control significantly de-
creased from 36.5% among the 25–34-year-old age
group (Table S4) to 17.1% among the 55–64-year-old
age group (OR: 0.27 [0.09–0.79]). Subsequently, control
insignificantly increased among individuals older than
65 years. Control was significantly associated with com-
plementary health insurance coverage (OR: 1.40 [1.06–
1.86]). In terms of lifestyle factors, individuals with a
lower control were more likely to be obese (OR: 0.56
[0.38–0.82]). Having a CVD history significantly in-
creased HTN control (OR: 2.06 [1.35–3.14]).
Based on the 2017 ACC/AHA, 68.2% of the hyperten-
sive individuals or 37.2% of the entire sample had either
BP ≥140/90 or BP ≥130/80 with 10-year ASCVD risk
≥10%, thus were eligible for pharmacologic therapy.
Whereas, based on JNC8, 95.7% of hypertensive individ-
uals and 28.6% of the entire sample were eligible for
pharmacologic therapy (Table 1). We also found that
among participants with BP > 120/80 mmHg, 97.9% were
eligible to reduce their salt intake to < 5 g/day, 89.6%
consumed insufficient amounts of fruits and vegetables,
69.4% were overweight or obese, and 57.2% were physic-
ally inactive.
The effects of lifestyle factors on SBP among adults eli-
gible for pharmacologic and non-pharmacologic therapy
are presented in Table 2. LDL cholesterol < 130mg/dL
had a large effect size, − 3.56 (− 4.38, − 2.74) mmHg. Just
one unit increase in BMI increased SBP by 0.48 (0.42,
0.53) mmHg. Being physically active significantly lowered
SBP (− 2.04 (− 2.58, − 1.50)) mmHg. The effect sizes of
sufficient intake of fruits and vegetables and salt intake
≥10 g/day were − 1.67 (− 2.49, − 0.86) and 1.52 (0.90, 2.13)
mmHg, respectively.
Discussion
Switching from JNC8 to the 2017 ACC/AHA created a
sharp rise in the prevalence and a drastic decline in
awareness, treatment, and control of HTN. Based on the
2017 ACC/AHA, half of the study samples fell into the
hypertensive category. Two-thirds of adults in the hyper-
tensive category were unaware, indicating that they were
undiagnosed. About one-third of those with awareness
remained untreated, and among those treated, less than
20% were under control.
The increase in prevalence upon using the 2017 ACC/
AHA guideline in Iran is consistent with a similar in-
crease in prevalence upon using this guideline in other
countries e.g. Nepal [21], China [9], and the United
States [24, 25]. By adopting the new guideline, the lar-
gest increase in prevalence was observed among young
and middle-aged individuals, which has also been re-
ported in China [9].
The prevalence and awareness of hypertension in Iran
(compared based on the cut-off of 140/90 mmHg) re-
semble findings reported in other middle-income coun-
tries [26, 27]. Despite a higher treatment rate in Iran, the
control rate stood at 39.1%, which is yet noticeably lower
than Turkey, with 53.9% in 2012, and Lebanon, with
54% in 2014 [28].
Increases in age significantly increased prevalence, aware-
ness, and treatment but decreased the control rate. The
likelihood of an increase in prevalence grew by a higher
BMI (overweight and obese), higher triglycerides, dyslipi-
daemia, diabetes, and previous CVD history. Studies also
reported a higher prevalence among the overweight, obese
[29, 30], diabetics, and those with a history of CVD [31].
Higher awareness and treatment rates were also observed
Table 1 Frequency and proportion of participants eligible for
pharmacologic and nonpharmacologic therapy*
Type of therapy % No. Sample
analysed
Eligible for pharmacologic
therapy based on 2017
ACC/AHA
Among samples 37.2 (36.2–38.2) 9746 26,718
Among hypertensive patients 68.2 (66.9–69.5) 9746 14,147
Eligible for pharmacologic
therapy based on JNC8
Among samples 28.6 (28.0–29.3) 7805 27,165
Among hypertensive patients 95.7 (95.2–96.1) 7805 8148
Nonpharmacologic
therapy
Being overweight
or obese
69.4 (68.6–70.2) 11,809 17,028
Insufficient intake of
fruits & vegetables
(fruits < 2 portions &
vegetables < 3 portions)
89.6 (88.9–90.3) 15,527 17,344
Salt Intake > 5 g/day 97.9 (97.6–98.3) 11,718 11,950
Salt Intake > 10 g/day ** 42.5 (41.4–43.7) 5208 11,950
Low physical activity
(METs < 600/week)
57.2 (56.3–58.2) 8958 15,721
LDL Cholesterol≥ 130
mg/dL
16.1 (15.3–16.9) 1989 12,248
*Nonpharmacologic therapy is recommended for all individuals with SBP
≥120 mmHg or DBP > 80mmHg (individuals with elevated, stage 1, and stage
2 hypertension) based on 2017 ACA/AHA
**Since less than 5% of study samples had a salt intake of less than 5 g/day,
we considered 10 g/day as the cut-off for the analysis of salt intake
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among those with comorbidities of diabetes and CVD [31].
This indicates a higher likelihood of diagnosis and treat-
ment in individuals living with such comorbidities.
Based on the 2017 ACC/AHA, a larger ratio of comor-
bid patients fell into the hypertensive category (24, 15, 17,
and 11% more individuals with dyslipidaemia, high triglyc-
erides, diabetes, and CVD events, respectively). Under this
guideline, many high-risk adults might be covered by
pharmacologic therapies and be protected against the pro-
gression of CVD and diabetic renal diseases [5, 32].
Based on the 2017 ACC/AHA, the proportion of par-
ticipants with BP > 120/80 mmHg who were eligible for
nonpharmacologic therapy was high. 97.9% of partici-
pants with BP > 120/80mmHg need to lower their salt
intake to < 5 g/day as recommended by the WHO [33];
89.6% need to consume sufficient fruits and vegetables,
and 69.4% need to lose extra weight.
Though the Tanaka formula provided statistically better
estimates for sodium intake in Iran [20], all three common
formulas used to estimate sodium intake (Kawasaki, Ta-
naka, and INTERSALT) were systematically biased with
overestimation at lower levels and underestimation at
higher levels of sodium intake [34]. In the light of this evi-
dence, we noted that the level of salt intake in Iran was
much higher than the 5 g/day cut-off recommended by
WHO, therefore even in the presence of underestimation
of sodium intake calculation, sodium intake levels exceeded
the recommended salt intake level. Thus, the percentage of
those eligible for reducing salt intake remained quite large.
Lifestyle factors, LDL cholesterol, physical activity, and
BMI had large effect sizes on lowering BP. Based on
these findings, non-pharmacologic therapy in hyperten-
sive patients may be considered to modify these lifestyle
factors. The modification of these lifestyle factors could
be a recommended therapy for low risk adults (ASCVD
< 10%) who fall into the hypertensive category under the
new guideline.
We contribute to a better understanding of the burden
of hypertension based on two distinctive guidelines. Con-
sidering the more aggressive cut-off point of 130/90
mmHg resulted in a greater prevalence and lower effective
coverage of hypertension. The largest increase in preva-
lence was observed in adults aged 25–34 years. Given the
large population of this age group (16.8 million) in Iran,
the number of adults who fall into the hypertensive cat-
egory remarkably increase from 1.2 million to 5.2 million
using the 2017 ACC/AHA. Despite the lowest awareness
and treatment rates in this young group, their control rate
was highest among all age groups. This implies that tar-
geting younger groups brings about greater benefits for
hypertension UHC programs and for the society through
maintaining health among the working as well as the re-
productive population of the country [35]. Given this po-
tential benefit for Iran, the use of the 2017 ACC/AHA
might also benefit other middle-income countries with
similar population profiles [9].
Though adopting 2017 ACC/AHA led to a higher preva-
lence, yet not all adults falling into the hypertensive cat-
egory were eligible for antihypertensive medications [5].
Based on the 2017 ACC/AHA, 37.2% of Iranian adults aged
> 25 years (17.2 million adults) were eligible for pharmaco-
logic therapy and based on JNC8 28.6% (13.4 million
adults) of them were [36]. With a minimum unit-cost of
treatment around $38 per person [37], pharmacologic ther-
apy would annually cost $653 million and $510 million, re-
spectively, under the 2017 ACC/AHA and JNC8 for all
Iranian adults aged > 25 years. Thus, the treatment costs in-
curred for pharmacotherapy by the health system under the
2017 ACC/AHA guideline was only marginally higher than
the treatment costs under the JNC8.
We found that hypertension was very poorly controlled
in Iran. Control is by nature a co-creational outcome.
Both patient behaviour and an effective structure and
process of care play roles in improving this outcome.
Based on our findings, patient adherence to a healthy life-
style and complementary insurance may improve the con-
trol rate [29, 30, 38]. We, however, call future research to
examine other dimensions of effective structures and pro-
cesses e.g. evidence-based care plan [39–41] and continu-
ity of care [42, 43] to improve hypertension control.
This research had several limitations, including the
challenge of causal inferences from cross-sectional data
and potential misclassifications of covariates. We claim
Table 2 Predicting factors of blood pressure among
participants eligible for pharmacologic and nonpharmacologic
therapy
Lifestyle characteristics Beta (effect size) 95% CI P value
Weight (kg) 0.003* −0.02, 0.02 0.725
BMI (kg/m2) 0.48 0.42, 0.53 < 0.001
Sufficient physical
activity †
−2.04 −2.58, −1.50 < 0.001
Intake of fruits &
vegetables ‡
−1.67 −2.49, −0.86 < 0.001
Salt intake§ 1.52 0.90–2.13 < 0.001
LDL Cholesterol < 130
mg/dL ||
−3.56 −4.38, −2.74 < 0.001
Alcohol consumption # 2.69 1.71, 3.66 < 0.001
*This is the only figure with three decimals in this table
†Individuals with sufficient Physical activity (PA) (METs≥600/week) were
compared against those with insufficient PA (METs< 600/week)
‡Intake of fruits and vegetables was compared between those who consumed
sufficient (fruits ≥2 portions & vegetables ≥3 portions) and insufficient
portions of fruits and vegetables (fruits < 2 portions & vegetables < 3 portions)
in 24 h
§Individuals with a salt intake of ≥10 g/day in 24 h were compared against
those with an intake of < 10 g/day
||Individuals with LDL cholesterol< 130 mg/dL were compared against those
with LDL cholesterol ≥130 mg/dL
#Non-drinker individuals were compared against drinkers
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no causal relationships as making causal inferences from
cross-sectional surveys is challenging. However, some of
our criteria do help infer causal relationships; we relied
on a compelling theoretical causal model with regards to
examining the determining factors for the prevalence,
awareness, treatment, and control of hypertension. This
was followed by the associations observed between the
focal variables as well as holding that the examined co-
variates and the causes logically precede these four out-
comes [44].
We are also aware that there are potential misclassifica-
tions of covariates, particularly salt intake and smoking.
We classified the participants based on 10 g/day cut-off
for salt intake rather than the 5 g/day recommended cut-
off point. We did so as a rather small number of our par-
ticipants had salt intakes of less than 5 g/day.
With regards to our classification of smoking status,
we classified never-smokers with former-smokers in the
same group, which may affect the magnitude of effects
this group has on the outcomes. The health outcomes of
a former-smoker might still be influenced by his/her
previous smoking history, which may offset the positive
effects of the never-smoker on the health outcomes of
interest [45]. Furthermore, the effect of smoking status
might be incompletely represented by our data choices.
We focused on cigarette only and other tobacco prod-
ucts were excluded from our analysis.
The external validity of our findings can be reasonably
maintained by the multistage random proportional to size
sampling employed. Participants were from all provinces
(except one province) and from both urban and rural
areas. Given this, the validity of inferences about the iden-
tified relationships might be, though not assuredly, main-
tained over variations in persons or times [46].
Conclusions
This manuscript applied a more progressive approach
toward the measurement of prevalence, awareness, treat-
ment, and control of hypertension services. The preva-
lence of hypertension markedly increased by the 2017
ACC/AHA guideline and at the same time awareness,
treatment, and control sharply declined. Based on the
2017 ACC/AHA, more than half the adults aged ≥25
years became hypertensive, which were mostly repre-
sented by the 25–34 age group. Since the control rate
among younger adults was higher than among older
adults, adopting the 2017 ACC/AHA guideline may
benefit the young population of Iran and in the same
way other middle-income countries with similar popula-
tion profiles.
The new guideline lowers the cut-off value for diagno-
sis and puts a higher proportion of adults in the hyper-
tensive category. Under this guideline, more individuals
with high triglycerides, diabetes, and CVD events fell
into a hypertensive category. Thus, by adopting the 2017
ACC/AHA a larger proportion of high-risk populations
would be eligible for UHC programs. Yet, not all adults
falling into a hypertensive category would need or re-
ceive antihypertensive medications; a large proportion of
them can be treated through lifestyle modifications,
based on the effect sizes reported in this study for LDL
cholesterol, physical activity, and BMI.
Based on either guideline, Iran has improved the per-
centage of hypertension treatment; however, the aware-
ness and particularly the control of hypertension remain
a challenge. To improve the control rate, efforts should
be made to improve both patient behaviour and the
quality of healthcare services.
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